Immunovant, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 5 | -$0.52 | -$0.52 | -$0.52 |
| Q2 2024 | 8 | -$0.59 | -$0.59 | -$0.59 |
| Q3 2024 | 10 | -$0.81 | -$0.56 | -$0.71 |
| Q1 2025 | 9 | -$0.81 | -$0.55 | -$0.72 |
| Q2 2025 | 8 | -$0.78 | -$0.78 | -$0.78 |
| Q3 2025 | 4 | -$0.81 | -$0.81 | -$0.81 |
| Q4 2025 | 5 | -$0.81 | -$0.81 | -$0.81 |
| Q1 2026 | 5 | -$0.84 | -$0.84 | -$0.84 |
Immunovant, Inc. Earnings Date And Information
Immunovant, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.74 earnings per share for the quarter, missing analysts' consensus estimates of $-0.61 by $0.13. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Immunovant, Inc. has generated $-2 earnings per share over the last year ($-1.88 diluted earnings per share) and currently has a price-to-earnings ratio of -12.16. Immunovant, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 10th, 2025 based on prior year's report dates.
Immunovant, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q2 2025 | -$0.61 | -$0.74 | -0.13 | $0 | $0 |
| 08/06/2024 | Q1 2025 | -$0.52 | -$0.60 | -0.08 | $0 | $0 |
| 05/29/2024 | Q4 2024 | -$0.43 | -$0.52 | -0.09 | $1.50 M | |
| 02/12/2024 | Q3 2024 | -$0.44 | -$0.36 | 0.08 | $0 | |
| 11/09/2023 | Q2 2024 | -$0.46 | -$0.45 | 0.01 | $0 | |
| 08/10/2023 | Q1 2024 | -$0.44 | -$0.57 | -0.13 | $0 | |
| 05/22/2023 | Q4 2023 | -$0.48 | -$0.46 | 0.02 | $0 | |
| 02/03/2023 | Q3 2023 | -$0.41 | -$0.49 | -0.08 | $0 | |
| 11/04/2022 | Q2 2023 | -$0.41 | -$0.41 | 0 | $0 | |
| 08/05/2022 | Q1 2023 | -$0.35 | $0 | |||
| 06/08/2022 | Q4 2022 | -$0.38 | -$0.41 | -0.03 | $0 | |
| 02/04/2022 | Q3 2022 | -$0.34 | -$0.36 | -0.02 | $0 | |
| 11/05/2021 | Q2 2022 | -$0.26 | -$0.35 | -0.09 | $0 | |
| 08/09/2021 | Q1 2022 | -$0.30 | -$0.31 | -0.01 | $0 | |
| 06/01/2021 | Q4 2021 | -$0.33 | -$0.29 | 0.04 | $0 | |
| 02/16/2021 | Q3 2021 | -$0.26 | -$0.32 | -0.06 | $0 | |
| 11/12/2020 | Q2 2021 | -$0.33 | -$0.21 | 0.12 | $0 | |
| 08/12/2020 | Q1 2021 | -$0.35 | -$0.32 | 0.03 | $0 | |
| 06/29/2020 | Q4 2020 | -$0.29 | $925,798 | |||
| 02/14/2020 | Q3 2020 | -$0.25 | -$0.28 | -0.03 | $0 |
Immunovant, Inc. Earnings: Frequently Asked Questions
-
When is Immunovant, Inc.'s earnings date?
Immunovant, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 10th, 2025 based off last year's report dates.
-
How can I listen to Immunovant, Inc.'s earnings conference call?
The conference call for Immunovant, Inc.'s latest earnings report can be listened to online.
-
How can I read Immunovant, Inc.'s conference call transcript?
The conference call transcript for Immunovant, Inc.'s latest earnings report can be read online.
-
How much profit does Immunovant, Inc. generate each year?
Immunovant, Inc. (:IMVT) has a recorded net income of $0. Immunovant, Inc. has generated $-1.88 earnings per share over the last four quarters.
-
What is Immunovant, Inc.'s price-to-earnings ratio?
Immunovant, Inc. (:IMVT) has a price-to-earnings ratio of -12.16 and price/earnings-to-growth ratio is 0.81.
